3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
43
Precursor Cell Lymphoblastic Leukemia-Lymphoma
14
Recurrence
7
Lymphoma, Non-Hodgkin
6
Burkitt Lymphoma
6
Neoplasms, Plasma Cell
5
Nausea
5
Leukemia
5
Vomiting
4
Prostatic Neoplasms
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasms
4
Lymphoma
4
Neoplasm Metastasis
3
Lymphoma, Large B-Cell, Diffuse
3
Hematologic Neoplasms
3
Amyloidosis
3
Smoldering Multiple Myeloma
2
Oligodendroglioma
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Leukemia, Biphenotypic, Acute
2
Immunoglobulin Light-chain Amyloidosis
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Astrocytoma
2
Waldenstrom Macroglobulinemia
1
Uveal Melanoma
1
Squamous Cell Carcinoma of Head and Neck
1
Spinal Cord Neoplasms
1
Interventions
pembrolizumab
11
epacadostat
2
Paclitaxel
2
spartalizumab
1
ribociclib
1
Surgical Procedures, Operative
1
Saline Solution
1
Radiosurgery
1
Prednisone
1
Pemetrexed
1
Nivolumab
1
Immunotherapy
1
Gemcitabine
1
Docetaxel
1
Dexamethasone
1
Cisplatin
1
Carboplatin
1
Calcium Dobesilate
1
Axitinib
1
AZD 6244
1
2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7H-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Calcium Dobesilate
×
Clear all
NCT04907227
2024-07-12
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3
Terminated
81 enrolled
19 charts